Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral DNX-2401 for Recurrent and Refractory High Grade Brain Tumors in Pediatric and Young Adult Patients
NCT07424092Phase 2Recruiting
- Sponsor
- Universidad de Navarra
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of Ad5-D24RGD in high-grade glioma (HGG), ependymoma, Embryonal tumor of the central nervous system, sponsored by Universidad de Navarra. Started May 2026; status: recruiting.
02
Drugs
Ad5-D24RGD
03
Conditions
high-grade glioma (HGG)ependymomaEmbryonal tumor of the central nervous system
Beyond the preview
Go deeper on NCT07424092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07424092.